Thursday, December 3, 2020

Pfizer Inc. (PFE) Stock Soars on ‘Near to End’ COVID-19 Vaccine

Must read

Oil Futures Saw Below 1% Decline, OPEC Still To Decide Upon Production Cuts

On Monday, November 30, after a rise of 1.1 percent during Friday trading, price of oil futures declined -0.4 percent to $45.34 per barrel...

U.S. Indices Started December With A Record Breaking Day

Wall Street began December on the right foot after gains of 11 percent to 12 percent for its key indices in November, with the...

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

The COVID-19 vaccine succeeds in the final stage trials while Pfizer agrees to make a $60 million equity investment in Homology. 

Shares of Pfizer, Inc. (PFE) soared up to 13% in the premarket following the update on the Phase 3 trials of the COVID-19 vaccine. The company along with BioNTech SE is eyeing towards achieving what the whole world has been waiting for.


My #1 Stock Trade This Year (HINT: It's a COVID-19 Play)

Get Ready for my next COVID-19 stock idea. I have been very fortunate in discovering biotech, therapeutic and diagnostic companies within the COVID-19 space, before wall street catches on. Our goal for our members is to get our Alert’s first before the crowd.    

>> Sign Up Now to Get Name & Ticker Symbol of Next Triple-Digit Gainer <<

Sponsored


The most wanted scientific advanceso far is the COVID-19 vaccine and Pfizer’s and BioNTech’s has come up with the most encouraging for it against the coronavirus battle.

The US pharmaceutical firm said that its mRNA-based vaccine candidate, BNT162b2, developed with German BioTech, is over 90% complete and shows an effective and efficient response in preventing SARS-CoV-2, the virus which causes COVID-19 infection.

Following the vaccine update, BioNTech shares surged 26%.

Pfizer shares are rallying with a heavy trading volume of 105 million. PFE kicked off the day at $41.86 jumping from the previous close of $36.40. As we write this at 11:11 A.M. EDT, PFE was trading at $39.83 soaring by 9.44%.

Pfizer Winning it for Humanity

More about the stake of the company and what it will bring to the firm, it is purely a statistical and technical or what we can say a business debate.

The entire world has suffered drastically from the global pandemic with over 1.25 million deaths. It is about humanity and Pfizer has become a big hope for the entire world. With this news circulating around the globe, people see Pfizer’s vaccine candidate as the most effective among all othersin the market.

The chairman and CEO of Pfizer, Dr. Albert Bourla said:

“Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19.”

The Phase 3 trials findings are based on an interim analysis gathered from 94 confirmed COVID-19 participants. The participants were split between the one’s who got vaccinated and those who got a placebo, contracted COVID-19.

The vaccine candidate, BNT162b2, was reported to have over 90% effectiveness in preventing from the virus. For further data collection, the Phase 3 study will continue until 164 cases are recorded.

If the data hold up and as per the anticipation of the company, a key safety readout, this could possibly be it when the world finally takes a deep breath as it would mean the beginning of an end to the global pandemic.

Pfizer, Inc. intends to submit for Emergency Use Authorization (EUA) to the FDA, as soon as, the company obtains the required safety milestone. It is expected that the final safety milestone would be achieved by the end of this month.

Followed by the vaccine update, Pfizer, Inc. (PFE) also announced that it has agreed to invest $60 million in Homology. The company will purchase 5 million common stock shares of Homology at a per share price of $12. The closing of this transaction is expected on Nov. 10, 2020.

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

U.S. Indices Started December With A Record Breaking Day

Wall Street began December on the right foot after gains of 11 percent to 12 percent for its key indices in November, with the...

Oil Futures Saw Below 1% Decline, OPEC Still To Decide Upon Production Cuts

On Monday, November 30, after a rise of 1.1 percent during Friday trading, price of oil futures declined -0.4 percent to $45.34 per barrel...

Death Toll In U.S. Could Reached 321,000 In A Month, Air Traveling Rose 22% This Week

In recent weeks, the outbreak of coronavirus has led to new travel restriction initiatives in a number of U.S. states and cities, including California,...

Spirit Airline (SAVE), United Airline (UAL) Stock Surged, Quicker Recovery Will Be The Key To Growth

Good news on the efficacy of COVID-19 vaccines confirms stocks from airlines that have been among the most impacted by social activity constraints. Optimism...

NVIDIA (NVDA) Stock Lost After Q3 Results, Record Revenues Did Not Help

The graphics chip (GPU) manufacturer NVIDIA Corp. (NVDA) issued its report for the third quarter of the fiscal year 2021 after the close of...

Get The Best Stocks To Trade Every Day!

Join now to get the DBTnews.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the DBTNews.com pre-market morning brief 100% free

We do not sell or share your information with anyone.